Latest news for Rainbow Rare Earths (OTC:RBWRF) Stock

Rainbow Rare Earths Ltd aims to be a forerunner in the establishment of an independent and ethical supply chain of the rare earth elements that are driving the green energy transition. It is doing this successfully via the identification and development of secondary rare earth deposits that can be brought into production quicker and at a lower cost than traditional hard rock mining projects, with a focus on the magnet rare earth elements neodymium & praseodymium, dysprosium & terbium. It is focused on the development of the Phalaborwa Project and the earlier stage Uberaba Project. Both projects entail the recovery of rare earths from phosphogypsum stacks that occur as the by-product of phosphoric acid production, with the original source rock for both deposits being a hardrock carbonatite.

RAINBOW RARE EARTHS LTD by RAINBOW RARE EARTHS LTD.

Rainbow Rare Earths Ltd

UBS analyst Jason Napier downgrades Lloyds Banking Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYG#NYSE">LYG</a>) from Buy to Neutral.

News

Downgrades

Analyst Ratings

UBS Downgrades Lloyds Banking Group to Neutral

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and raises the price target from $40 to $45.

Price Target

CORT

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $45

Needham analyst Mike Matson reiterates NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) with a Buy and maintains $19 price target.

Reiteration

Needham Reiterates Buy on NeoGenomics, Maintains $19 Price Target

WIIM

Merck shares re trading higher following a Q2 earnings beat but mixed guidance.

Seaport Global analyst Sunil Sibal downgrades Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) from Buy to Neutral.

Seaport Global Downgrades Williams Companies to Neutral

AMKR

Amkor Technology shares are trading lower after the company issued roughly inline guidance.

For the full year of 2024, Civeo is maintaining its previously provided revenue and Adjusted EBITDA&nbsp;guidance&nbsp;ranges of&nbsp;$625 million&nbsp;to&nbsp;$700 million&nbsp;and&nbsp;$80 million&nbsp;to&nbsp;$90 million, respectively. The Company is also maintaining its full year 2024 capital expenditure&nbsp;guidance&nbsp;of&nbsp;$30 million&nbsp;to&nbsp;$35 million.

Guidance

CVEO

Civeo Is Maintaining Previously Provided FY24 Revenue Guidance Range Of $625M-$700M Vs. $665.18M Estimate

Biotech

Earnings

Large Cap

Health Care

General

Merck Expects 2024 Adjusted EPS Of $7.94-$8.04 Compared To Prior Guidance Of  $8.53-$8.65 And Consensus Of $8.16, Includes One-time Charges Totaling $0.77 Per Share For The Harpoon And Eyebio Acquisitions

Citigroup analyst Joanne Wuensch downgrades Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) from Neutral to Sell and lowers the price target from $30 to $23.

IART

Citigroup Downgrades Integra Lifesciences to Sell, Lowers Price Target to $23

SITE Centers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.24 by 12.5 percent. This is a 6.9 percent decrease over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $114.129 million which beat the analyst consensus estimate of $113.504 million by 0.55 percent. This is a 16.32 percent decrease over sales of $136.383 million the same period last year.

Earnings Beats

SITC

SITE Centers Q2 2024 FFO $0.27 Beats $0.24 Estimate, Sales $114.129M Beat $113.504M Estimate

LSCC

Lattice Semiconductor shares are trading lower after the company reported worse-than-expected Q2 financial results and issued weak Q3 revenue guidance.

Eagle Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXP#NYSE">EXP</a>) reported quarterly earnings of $3.94 per share which beat the analyst consensus estimate of $3.78 by 4.23 percent. The company reported quarterly sales of $608.689 million which missed the analyst consensus estimate of $624.182 million by 2.48 percent. This is a 1.19 percent increase over sales of $601.521 million the same period last year.

Earnings Misses

Eagle Materials Q1 2025 GAAP EPS $3.94 Beats $3.78 Estimate, Sales $608.689M Miss $624.182M Estimate

Needham analyst Ryan Koontz reiterates Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) with a Buy and maintains $18 price target.

HLIT

Needham Reiterates Buy on Harmonic, Maintains $18 Price Target

Full-Year 2024 Financial Outlook
The following table summarizes the company&#39;s full-year financial outlook.
<table cellspacing="0">
<tbody>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="2" rowspan="1">
Full Year 2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
Updated
</td>
<td colspan="1" rowspan="1">
Prior
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Sales&#x2A;
</td>
<td colspan="1" rowspan="1">
$63.4 to $64.4 billion
</td>
<td colspan="1" rowspan="1">
$63.1 to $64.3 billion
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP Gross margin2
</td>
<td colspan="1" rowspan="1">
Approximately 81%
</td>
<td colspan="1" rowspan="1">
Approximately 81%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAPOperating expenses2&#x2A;&#x2A;
</td>
<td colspan="1" rowspan="1">
$26.8 to $27.6 billion
</td>
<td colspan="1" rowspan="1">
$25.2 to $26.1 billion
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAPOther (income) expense, net2
</td>
<td colspan="1" rowspan="1">
Approximately $350 million expense
</td>
<td colspan="1" rowspan="1">
Approximately $250 million expense
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAPEffective tax rate2
</td>
<td colspan="1" rowspan="1">
15.5% to 16.5%
</td>
<td colspan="1" rowspan="1">
14.5% to 15.5%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAPEPS2&#x2A;&#x2A;&#x2A;
</td>
<td colspan="1" rowspan="1">
$7.94 to $8.04
</td>
<td colspan="1" rowspan="1">
$8.53 to $8.65
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Share count (assuming dilution)
</td>
<td colspan="1" rowspan="1">
Approximately 2.54 billion
</td>
<td colspan="1" rowspan="1">
Approximately 2.55 billion
</td>
</tr>
</tbody>
</table>

Merck Expects 2024 Sales Of $63.4B-$64.4B Compared To Prior Guidance Of $63.1B-$64.3B And Consensus Of $64.341B

TLRY

Tilray Brands shares are trading higher after the company reported better-than-expected Q4 financial results.

B of A Securities analyst Blake Friedman downgrades Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) from Neutral to Underperform and lowers the price target from $83 to $47.

B of A Securities Downgrades Lattice Semiconductor to Underperform, Lowers Price Target to $47

Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.21 by 166.67 percent. This is a 86.67 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $188.71 million which beat the analyst consensus estimate of $173.70 million by 8.64 percent. This is a 5.52 percent increase over sales of $178.84 million the same period last year.

Civeo Q2 GAAP EPS $0.56 Beats $0.21 Estimate, Sales $188.71M Beat $173.70M Estimate

Graphic Packaging Sees FY24 Adj EPS Of $2.65 - $2.85 Vs. $2.67 Est.

FFIV

F5 shares are trading higher after the company reported better-than-expected Q3 financial results. Additionally, the company raised its FY24 earnings guidance above estimates.

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Rainbow Rare Earths

News

Latest news for Rainbow Rare Earths (OTC:RBWRF) Stock